IP Verse

Modulation Of Alpha Synuclein Expression - EP2640853

The patent EP2640853 was granted to Ionis Pharmaceuticals on Dec 26, 2018. The application was originally filed on Nov 17, 2011 under application number EP11840796A. The patent is currently recorded with a legal status of "Revoked".

EP2640853

IONIS PHARMACEUTICALS
Application Number
EP11840796A
Filing Date
Nov 17, 2011
Status
Revoked
Oct 21, 2024
Grant Date
Dec 26, 2018
External Links
Slate, Register, Google Patents

Patent Summary

Patent Family

Patent Family

Patent Oppositions

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentativeOpposition Status

Get instant alerts for new oppositions and patent status changes

HOFFMANN EITLESep 25, 2019HOFFMANN EITLEADMISSIBLE

Patent Citations (62) New

Patent citations refer to prior patents cited during different phases such as opposition or international search.

Citation PhasePublication NumberPublication Link
DESCRIPTIONUS20070989574-
DESCRIPTIONUS20080026995-
DESCRIPTIONUS20080026998-
DESCRIPTIONUS20080056564-
DESCRIPTIONUS20080086231-
DESCRIPTIONUS20080097787-
DESCRIPTIONUS20080099844-
DESCRIPTIONUS20080915408-
DESCRIPTIONWO2008US64591-
DESCRIPTIONWO2008US66154-
DESCRIPTIONWO2008US68922-
DESCRIPTIONUS2004171570
DESCRIPTIONUS2005130923
DESCRIPTIONUS2007213366
DESCRIPTIONUS2007287831
DESCRIPTIONUS2008039618
DESCRIPTIONUS2008300204
DESCRIPTIONUS2008306143
DESCRIPTIONUS2009123575
DESCRIPTIONUS2009286745
DESCRIPTIONUS2010031377
DESCRIPTIONUS2010036122
DESCRIPTIONUS2010056622
DESCRIPTIONUS2010179223
DESCRIPTIONUS2010261753
DESCRIPTIONUS2010278814
DESCRIPTIONUS6268490
DESCRIPTIONUS6525191
DESCRIPTIONUS6670461
DESCRIPTIONUS6770748
DESCRIPTIONUS6794499
DESCRIPTIONUS7034133
DESCRIPTIONUS7053207
DESCRIPTIONUS7399845
DESCRIPTIONUS7427672
DESCRIPTIONUS7727957
DESCRIPTIONUS7763747
DESCRIPTIONWO03004602
DESCRIPTIONWO2004106356
DESCRIPTIONWO2005021570
DESCRIPTIONWO2007134181
DESCRIPTIONWO2008101157
DESCRIPTIONWO2008150729
DESCRIPTIONWO2008154401
DESCRIPTIONWO2009006478
DESCRIPTIONWO2009079399
DESCRIPTIONWO9414226
DESCRIPTIONWO9839352
DESCRIPTIONWO9914226
INTERNATIONAL-SEARCH-REPORTUS2007225209
INTERNATIONAL-SEARCH-REPORTUS2008003570
INTERNATIONAL-SEARCH-REPORTUS2009092981
INTERNATIONAL-SEARCH-REPORTUS2010204306
INTERNATIONAL-SEARCH-REPORTUS5102785
INTERNATIONAL-SEARCH-REPORTUS6833361
INTERNATIONAL-SEARCH-REPORTUS7750141
OPPOSITIONUS2008003570
OPPOSITIONWO2006034348
OPPOSITIONWO2009079399
OPPOSITIONWO2012068405
SEARCHWO2007135426
SEARCHWO2009079399

Non-Patent Literature (NPL) Citations (9) New

NPL citations refer to non-patent references such as research papers, articles, or other publications cited during examination or opposition phases.

Citation PhaseReference TextLink
EXAMINATION- Z. J. Lu ET AL, "Fundamental differences in the equilibrium considerations for siRNA and antisense oligodeoxynucleotide design", Nucleic Acids Research, (20080515), vol. 36, no. 11, doi:10.1093/nar/gkn266, ISSN 0305-1048, pages 3738 - 3745, XP055347254
OPPOSITION- HENRY et al., "Chemically Modified Oligonucleotides Exhibit Decreased Immune Stimulation in Mice", J of Pharmacology and Experimental Therapeutics, (20000000), vol. 292, no. 2, pages 468 - 479, XP002310045-
OPPOSITION- MURPHY et al., "Synucleins Are Developmentally Expressed, and α-Synuclein Regulates the Size of the Presynaptic Vesicular Pool in Primary Hippocampal Neurons", J of Neurosc, (20000000), vol. 20, no. 9, doi:10.1523/JNEUROSCI.20-09-03214.2000, ISSN 0270-6474, pages 3214 - 3220, XP055154387-
OPPOSITION- MAGUIRE-ZEISS K, "α-Synuclein: A therapeutic target for Parkinson’s disease?", Pharmacol Res, (20080000), vol. 58, no. 5-6, doi:10.1016/j.phrs.2008.09.006, ISSN 1043-6618, pages 271 - 280, XP025713301
OPPOSITION- VICKERS et al., Nucleic Acids Research, (20000000), vol. 28, doi:10.1093/nar/28.6.1340, ISSN 0305-1048, pages 1340 - 1347, XP001084042
OPPOSITION- CHAN et al., "ANTISENSE OLIGONUCLEOTIDES: FROM DESIGN TO THERAPEUTIC APPLICATION", Clin and Exp Pharmacology and Physiology, (20060000), vol. 33, no. 5-6, doi:10.1111/j.1440-1681.2006.04403.x, ISSN 0305-1870, pages 533 - 540, XP008158920
SEARCH- Diane D. Murphy et al., "Synucleins Are developmentally expressed, and alpha-Synuclein regulates the size of the presynaptic vesicular pool in primary hippocampal neurons", Journal of Neuroscience, UNITED STATES, (20000501), page 3214, URL: http://www.jneurosci.org/cgi/content/abstract/20/9/3214, (20141121), XP055154387 [X] 1,2,4,11,12 * the whole document *-
SEARCH- SHUMIN LIU ET AL., "[alpha]-Synuclein produces a long-lasting increase in neurotransmitter release", THE EMBO JOURNAL, (20041110), vol. 23, no. 22, doi:10.1038/sj.emboj.7600451, ISSN 0261-4189, pages 4506 - 4516, XP055154382 [X] 1,2,4,11,12 * the whole document *
SEARCH- BARBARA MONTI ET AL., "Alpha-synuclein protects cerebellar granule neurons against 6-hydroxydopamine-induced death", JOURNAL OF NEUROCHEMISTRY, (20070618), vol. 103, no. 2, doi:10.1111/j.1471-4159.2007.04778.x, ISSN 0022-3042, pages 518 - 530, XP055154364 [X] 1,2,4,11,12 * the whole document *

Download Citation Report

Get a free citation report including examiner, opposition, and international search citations.

Get Citation Report

Dossier Documents

The dossier documents provide a comprehensive record of the patent’s prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent’s legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents